Sept. 16, 2026 — Ultrasound AI, Inc., a developer of artificial intelligence for medical imaging with a focus on maternal-fetal health, has announced the issuance of two U.S. patents, bringing its U.S. portfolio to six granted patents. Issued on Sept. 1 and Sept. 15, the patents address pharmaceutical-exposure analysis and comprehensive medical assessment through medical imaging.
The new patents expand the company’s intellectual property portfolio around using artificial intelligence to extract clinically relevant information from medical images. They reflect research extending from Ultrasound AI’s foundations in pregnancy imaging to additional potential applications in medicine.
“Our goal is to turn the information in medical images into insights that help clinicians make more informed decisions,” said Robert Bunn, founder and CEO of Ultrasound AI. “These patents reflect the breadth of our research and strengthen the intellectual property foundation for our work. Our focus remains bringing carefully developed AI into maternal-fetal care, where better information can make a meaningful difference for families.”
The two patents are:
-
U.S. Patent No. 12,721,589 B2, issued Sept. 1, 2026, titled Artificial Intelligence System for Determining Drug Use Through Medical Imaging. The patent describes methods for training neural networks to estimate pharmaceutical exposure from medical images, including selecting relevant imaging information and filtering images based on quality or usefulness to the analysis.
-
U.S. Patent No. 12,733,901, issued Sept. 15, 2026, titled Artificial Intelligence System for Comprehensive Medical Diagnosis, Prognosis, and Treatment Optimization Through Medical Imaging. The invention describes approaches to analyzing medical images and underlying imaging data to generate information relevant to medical assessment, prognosis and treatment planning.
The additions build on Ultrasound AI’s existing U.S. patents concerning premature-birth prediction and the determination of clinical values through medical imaging. The company also holds patents in Israel, Singapore, Japan and South Korea, with additional applications pending in the United States and internationally. The full patent portfolio can be found at ultrasound.ai/patents.
Issued patents cover inventions and methods, and do not reflect the FDA-authorized indications for use of any Ultrasound AI product.
September 15, 2026 
